NO329848B1 - Anvendelse av rekonstituert HDL - Google Patents

Anvendelse av rekonstituert HDL Download PDF

Info

Publication number
NO329848B1
NO329848B1 NO20030137A NO20030137A NO329848B1 NO 329848 B1 NO329848 B1 NO 329848B1 NO 20030137 A NO20030137 A NO 20030137A NO 20030137 A NO20030137 A NO 20030137A NO 329848 B1 NO329848 B1 NO 329848B1
Authority
NO
Norway
Prior art keywords
rhdl
use according
treatment
infusion
apolipoprotein
Prior art date
Application number
NO20030137A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030137L (no
NO20030137D0 (no
Inventor
Peter Lerch
Thomas F Luescher
Georg Noll
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Publication of NO20030137L publication Critical patent/NO20030137L/no
Publication of NO20030137D0 publication Critical patent/NO20030137D0/no
Publication of NO329848B1 publication Critical patent/NO329848B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Supports For Pipes And Cables (AREA)
  • External Artificial Organs (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20030137A 2000-07-20 2003-01-10 Anvendelse av rekonstituert HDL NO329848B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10035352A DE10035352A1 (de) 2000-07-20 2000-07-20 Verfahren zur Behandlung von instabiler Angina pectoris
PCT/EP2001/008425 WO2002007753A2 (de) 2000-07-20 2001-07-20 Verfahren zur behandlung von instabiler angina pectoris

Publications (3)

Publication Number Publication Date
NO20030137L NO20030137L (no) 2003-01-10
NO20030137D0 NO20030137D0 (no) 2003-01-10
NO329848B1 true NO329848B1 (no) 2011-01-10

Family

ID=7649620

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030137A NO329848B1 (no) 2000-07-20 2003-01-10 Anvendelse av rekonstituert HDL

Country Status (17)

Country Link
US (1) US7053049B2 (pl)
EP (1) EP1303294B1 (pl)
JP (1) JP4928047B2 (pl)
KR (2) KR20070108955A (pl)
AT (1) ATE333887T1 (pl)
AU (2) AU2001282004B2 (pl)
CA (1) CA2418238C (pl)
DE (2) DE10035352A1 (pl)
DK (1) DK1303294T3 (pl)
ES (1) ES2266234T3 (pl)
HU (1) HU230151B1 (pl)
IL (2) IL154006A0 (pl)
NO (1) NO329848B1 (pl)
NZ (1) NZ523784A (pl)
PL (1) PL204406B1 (pl)
WO (1) WO2002007753A2 (pl)
ZA (1) ZA200300509B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US7956035B2 (en) * 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
WO2014051549A1 (en) 2012-09-25 2014-04-03 Hewlett-Packard Development Company, L.P. Drop detection
ITMI20131300A1 (it) * 2013-08-01 2015-02-02 Nobil Bio Ricerche Srl Composizione per il riempimento di difetti ossei e parodontali
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
GB2603950B (en) 2021-02-22 2025-04-23 Reckitt & Colman Overseas Hygiene Home Ltd Effervescent germicidal compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
SG48108A1 (en) * 1991-11-22 1998-04-17 Lipogenenics Inc Tocotrienols and tocotrienol-like compounds and methods for their use
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
JPH10218861A (ja) * 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AU777788B2 (en) * 1999-11-26 2004-10-28 Heart Research Institute Limited, The Oxidized apolipoproteins and methods of use
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Also Published As

Publication number Publication date
DE10035352A1 (de) 2002-01-31
US7053049B2 (en) 2006-05-30
ZA200300509B (en) 2004-02-17
US20040014654A1 (en) 2004-01-22
AU8200401A (en) 2002-02-05
KR20070108955A (ko) 2007-11-13
DE50110552D1 (de) 2006-09-07
PL366395A1 (pl) 2005-01-24
EP1303294A2 (de) 2003-04-23
DK1303294T3 (da) 2006-10-30
HU230151B1 (hu) 2015-09-28
HUP0300730A3 (en) 2010-07-28
CA2418238C (en) 2012-06-05
EP1303294B1 (de) 2006-07-26
ES2266234T3 (es) 2007-03-01
HUP0300730A2 (hu) 2003-12-29
CA2418238A1 (en) 2003-01-16
NO20030137L (no) 2003-01-10
WO2002007753A3 (de) 2003-02-13
IL154006A (en) 2010-05-31
IL154006A0 (en) 2003-07-31
WO2002007753A2 (de) 2002-01-31
JP4928047B2 (ja) 2012-05-09
ATE333887T1 (de) 2006-08-15
PL204406B1 (pl) 2010-01-29
KR20030026980A (ko) 2003-04-03
KR100864079B1 (ko) 2008-10-16
JP2004504355A (ja) 2004-02-12
AU2001282004B2 (en) 2006-02-02
NO20030137D0 (no) 2003-01-10
NZ523784A (en) 2004-06-25

Similar Documents

Publication Publication Date Title
Li et al. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation
Oudegeest-Sander et al. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial
EP2749281B1 (en) Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
Itoh et al. The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors
Novo et al. Prevalence of risk factors in patients with peripheral arterial disease
NO329848B1 (no) Anvendelse av rekonstituert HDL
Ono et al. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function
US20180140579A1 (en) Sacubitril and valsartan for treating metabolic disease
US11752122B2 (en) N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated TGF-beta activation and signaling
KR20210013543A (ko) 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도
Gasic et al. Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.
Weiss Lipid apheresis and rheopheresis for treatment of peripheral arterial disease
Ruxer et al. ``White coat hypertension''in type 2 diabetic patients
CATRINA et al. A CASE REPORT OF AN AORTIC FLOATING THROMBUS WITH PERIPHERAL EMBOLIZATION IN A 29-YEAR OLD APPARENTLY HEALTHY SUBJECT
Kostov Cardiovascular risk in patients with type 1 diabetes
Gill et al. A sodium channel enhancer, LY341311, increases myocardial contractile performance without increasing heart rate in conscious normal dogs: A comparison with dobutamine
US20080176810A1 (en) Use of 3, 4', 5-Trihydroxy-Stilbene-3-Beta-D-glucoside in Prepartion of Medicines For Treating and/or Preventing Ischemic Heart Disease
JP2022510403A (ja) 虚血傷害および虚血再灌流傷害の予防および／または治療のための方法および組成物
Bloomgarden American Diabetes Association Annual Meeting, 1998: cardiac disease and related topics
He et al. Workshop 9 O50
Warner et al. Hypoxia induced iNOS expression in cardiac myocytes is mediated by binding to both the hypoxia responsive element and NFκB binding site
Shashurin et al. EFFECTS OF BETA-BLOCKERS ON PEROXIDE OXIDATION IN ISCHEMIC MODEL OF CONGESTIVE HEART FAILURE IN RATS: PP. 40.306
STRANO et al. Pathophysiology, University of Catania and** Institute of clinical Medicine of uni
Klimas et al. EFFECTS OF TESTOSTERONE ON CARDIAC FUNCTION IN PHYSICALLY ACTIVE RATS: PP. 40.307
US20190008798A1 (en) Coenzyme Q10 in the preventive treatment of type 2 diabetes

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees